Literature DB >> 18597173

A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic.

Leo Bastiaens1.   

Abstract

Forty-six patients (36 male, mean age 11.9 +/- 2.6) with a variety of diagnoses and with significant aggressive behavior were treated in an open, non-randomized fashion with Aripiprazole or Ziprasidone. Patients were diagnosed with the Mini International Neuropsychiatric Interview and the Child/Adolescent Symptom Inventory. The primary outcome measure was the Overt Aggression Scale (OAS). After 2 months, 34 patients were still in treatment. The average improvement of the OAS in these 34 patients was 63%. Clinical Global Impression-Improvement Scale was 2.1 +/- 1.2. Neither at baseline, nor at 2 months, were there any statistically significant differences between the Aripiprazole and Ziprasidone groups. Sedation was the most common side effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18597173     DOI: 10.1007/s10597-008-9154-7

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  16 in total

Review 1.  Antipsychotic medications for children and adolescents.

Authors:  B L Gracious; R L Findling
Journal:  Pediatr Ann       Date:  2001-03       Impact factor: 1.132

Review 2.  Consensus development conference on antipsychotic drugs and obesity and diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

3.  Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

Authors:  Andrés Martin; Lawrence Scahill; George M Anderson; Michael Aman; L Eugene Arnold; James McCracken; Christopher J McDougle; Elaine Tierney; Shirley Chuang; Benedetto Vitiello
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

4.  A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.

Authors:  J K Buitelaar; R J van der Gaag; P Cohen-Kettenis; C T Melman
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

5.  The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review.

Authors:  Drew H Barzman; Melissa P DelBello; Robert A Kowatch; Beth Gernert; David E Fleck; Sanjeev Pathak; Katherine Rappaport; Sergio V Delgado; Pamela Campbell; Stephen M Strakowski
Journal:  J Child Adolesc Psychopharmacol       Date:  2004       Impact factor: 2.576

6.  Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000.

Authors:  Nick C Patel; Robert J Sanchez; Michael T Johnsrud; M Lynn Crismon
Journal:  J Child Adolesc Psychopharmacol       Date:  2002       Impact factor: 2.576

Review 7.  Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents.

Authors:  Nick C Patel; M Lynn Crismon; Kimberly Hoagwood; Peter S Jensen
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-04       Impact factor: 2.576

8.  A double-blind pilot study of risperidone in the treatment of conduct disorder.

Authors:  R L Findling; N K McNamara; L A Branicky; M D Schluchter; E Lemon; J L Blumer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-04       Impact factor: 8.829

Review 9.  Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.

Authors:  Brian J McConville; Michael T Sorter
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

Review 10.  Psychopharmacologic treatment of aggression in children and adolescents.

Authors:  Steven Ruths; Hans Steiner
Journal:  Pediatr Ann       Date:  2004-05       Impact factor: 1.132

View more
  6 in total

1.  Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.

Authors:  Fausto A Varela; Taleen Der-Ghazarian; Ryan J Lee; Sergios Charntikov; Cynthia A Crawford; Sanders A McDougall
Journal:  J Psychopharmacol       Date:  2013-09-17       Impact factor: 4.153

2.  Focus on aripiprazole: a review of its use in child and adolescent psychiatry.

Authors:  Masa'il Greenaway; Dean Elbe
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2009-08

3.  Harms of Antipsychotics in Children and Young Adults: A Systematic Review Update.

Authors:  Jennifer Pillay; Khrista Boylan; Amanda Newton; Lisa Hartling; Ben Vandermeer; Megan Nuspl; Tara MacGregor; Robin Featherstone; Normand Carrey
Journal:  Can J Psychiatry       Date:  2018-06-04       Impact factor: 4.356

4.  Severely Mood-disordered Youth Respond Less Well to Treatment in a Community Clinic than Youth with Bipolar Disorder.

Authors:  Leo Bastiaens; Jesse Bastiaens
Journal:  Psychiatry (Edgmont)       Date:  2008-10

Review 5.  Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis.

Authors:  Chiara Bernagie; Marina Danckaerts; Martien Wampers; Marc De Hert
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

6.  Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.

Authors:  Anne Katrine Pagsberg; Pia Jeppesen; Dea Gowers Klauber; Karsten Gjessing Jensen; Ditte Rudå; Marie Stentebjerg-Olesen; Peter Jantzen; Simone Rasmussen; Eva Ann-Sofie Saldeen; Maj-Britt Glenn Lauritsen; Niels Bilenberg; Anne Dorte Stenstrøm; Jesper Pedersen; Louise Nyvang; Sarah Madsen; Marlene B Lauritsen; Ditte Lammers Vernal; Per Hove Thomsen; Jakob Paludan; Thomas M Werge; Kristian Winge; Klaus Juul; Christian Gluud; Maria Skoog; Jørn Wetterslev; Jens Richardt M Jepsen; Christoph U Correll; Anders Fink-Jensen; Birgitte Fagerlund
Journal:  BMC Psychiatry       Date:  2014-07-11       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.